3 completed, 1 suspended, 1 terminated. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Suspended 1, Terminated 1 |
Follow Recurrent Hematologic Malignancy: new trials by email Literature Review of Recurrent Hematologic Malignancy trials Research Report on Recurrent Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Fructooligosaccharide, Laboratory Biomarker Analysis - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hematologic Malignancy | Phase 1 | Completed | Stanford University | 15 | 2016-06-01 | 2021-03-23 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Suspended | University of Chicago | 30 | 2014-12-05 | 2026-03-30 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 71 | 2013-05-16 | 2021-06-24 |
Hematologic Neoplasms (5) · Hodgkin Disease (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Anemia (1) · Blast Crisis (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Leukemia, Lymphoid (4) · Leukemia, Myeloid (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms by Histologic Type (4) · Bone Marrow Diseases (3) · Chronic Disease (3) · Disease Attributes (3)
CTLA-4 Antigen (2) · Ipilimumab (2) · Nivolumab (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · Acetaminophen (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Bortezomib (1) · Calcium Dobesilate (1) · Capecitabine (1) · Carboplatin (1) · Celecoxib (1)
City of Hope Medical Center (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Stanford University (1) · University of Chicago (1)
United States (5)
Andrew Rezvani (1) · Hongtao Liu (1) · Ibrahim T Aldoss (1) · Lara Davis, MD (1) · Matthew S Davids (1) · Tessa Andermann (1)
PMID 27410923, PMID 32478814, PMID 33720354, PMID 35622074, PMID 39863139
P30CA006516 (1), P30CA014599 (1), P30CA033572 (1), P30CA124435 (1), R01CA183559 (1), U01CA062490 (1), UM1CA186709 (1)